PMID- 30203901
OWN - NLM
STAT- MEDLINE
DCOM- 20191227
LR  - 20191227
IS  - 1440-1797 (Electronic)
IS  - 1320-5358 (Linking)
VI  - 24
IP  - 7
DP  - 2019 Jul
TI  - Systemic immune-inflammation index could estimate the cross-sectional high 
      activity and the poor outcomes in immunosuppressive drug-naive patients with 
      antineutrophil cytoplasmic antibody-associated vasculitis.
PG  - 711-717
LID - 10.1111/nep.13491 [doi]
AB  - OBJECTIVES: We investigated whether systemic immune-inflammation index (SII) at 
      diagnosis can estimate the cross-sectional high activity and predict the poor 
      outcomes in immunosuppressive drug-naive patients with antineutrophil cytoplasmic 
      antibody-associated vasculitis (AAV). METHODS: We retrospectively reviewed the 
      medical records of 163 patients with AAV and obtained clinical and laboratory 
      data. We calculated Birmingham vasculitis activity score (BVAS) as well as 
      five-factor score (FFS) (2009) at diagnosis. SII at diagnosis was calculated by 
      the equation of (SII at diagnosis = platelet count x neutrophil count/lymphocyte 
      count at diagnosis). Severe AAV was defined as BVAS at diagnosis >/=16. The odds 
      ratio was assessed using the multivariable logistic regression analysis and 
      cumulative survival rates were compared by the Kaplan-Meier survival analysis. 
      RESULTS: The median age at diagnosis was 58.0 years old and 51 patients were men. 
      The median BVAS was 12.0. Fifty-seven patients had severe AAV. The median SII at 
      diagnosis was 1349.6. In the multivariable analysis, only SII exhibited a 
      significant odds ratio for the cross-sectional severe AAV (P = 0.043). We 
      obtained the cut-off of SII at diagnosis for severe AAV as 1573.56. Patients with 
      SII at diagnosis >/=1573.56 exhibited a significantly high relative risk of the 
      cross-sectional severe AAV compared to those without (relative risk 4.625). 
      Furthermore, patients with SII at diagnosis >/=1573.56 exhibited significantly the 
      lower cumulative relapse free and renal survivals than those without. CONCLUSION: 
      Systemic immune-inflammation index at diagnosis could estimate the cross-section 
      severe AAV and predict the poor outcomes in AAV patients.
CI  - (c) 2018 Asian Pacific Society of Nephrology.
FAU - Kim, Youhyun
AU  - Kim Y
AD  - Deparment of Medicine, Yonsei University College of Medicine, Seoul, Republic of 
      Korea.
FAU - Choi, Hyeok
AU  - Choi H
AD  - Deparment of Medicine, Yonsei University College of Medicine, Seoul, Republic of 
      Korea.
FAU - Jung, Seung Min
AU  - Jung SM
AD  - Division of Rheumatology, Department of Internal Medicine, Yonsei University 
      College of Medicine, Seoul, Republic of Korea.
FAU - Song, Jason Jungsik
AU  - Song JJ
AD  - Division of Rheumatology, Department of Internal Medicine, Yonsei University 
      College of Medicine, Seoul, Republic of Korea.
AD  - Institute for Immunology and Immunological Diseases, Yonsei University College of 
      Medicine, Seoul, Republic of Korea.
FAU - Park, Yong-Beom
AU  - Park YB
AD  - Division of Rheumatology, Department of Internal Medicine, Yonsei University 
      College of Medicine, Seoul, Republic of Korea.
AD  - Institute for Immunology and Immunological Diseases, Yonsei University College of 
      Medicine, Seoul, Republic of Korea.
FAU - Lee, Sang-Won
AU  - Lee SW
AD  - Division of Rheumatology, Department of Internal Medicine, Yonsei University 
      College of Medicine, Seoul, Republic of Korea.
AD  - Institute for Immunology and Immunological Diseases, Yonsei University College of 
      Medicine, Seoul, Republic of Korea.
LA  - eng
GR  - 6-2016-0145/Yonsei University College of Medicine/
PT  - Journal Article
DEP - 20190429
PL  - Australia
TA  - Nephrology (Carlton)
JT  - Nephrology (Carlton, Vic.)
JID - 9615568
RN  - 0 (Immunosuppressive Agents)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/*drug 
      therapy/immunology/mortality
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - Immunosuppressive Agents/*therapeutic use
MH  - Inflammation/*immunology
MH  - Kidney Failure, Chronic/etiology
MH  - Logistic Models
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Retrospective Studies
OTO - NOTNLM
OT  - activity
OT  - antineutrophil cytoplasmic antibody-associated vasculitis
OT  - systemic immune-inflammation index
EDAT- 2018/09/12 06:00
MHDA- 2019/12/28 06:00
CRDT- 2018/09/12 06:00
PHST- 2018/09/07 00:00 [accepted]
PHST- 2018/09/12 06:00 [pubmed]
PHST- 2019/12/28 06:00 [medline]
PHST- 2018/09/12 06:00 [entrez]
AID - 10.1111/nep.13491 [doi]
PST - ppublish
SO  - Nephrology (Carlton). 2019 Jul;24(7):711-717. doi: 10.1111/nep.13491. Epub 2019 
      Apr 29.